DHODH-IN-23

CAS No. 1346705-53-0

DHODH-IN-23( —— )

Catalog No. M36042 CAS No. 1346705-53-0

DHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 46 Get Quote
10MG 72 Get Quote
25MG 159 Get Quote
50MG 251 Get Quote
100MG 356 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DHODH-IN-23
  • Note
    Research use only, not for human use.
  • Brief Description
    DHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.
  • Description
    DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.
  • In Vitro
    Cell Proliferation Assay Cell Line:U937, HL-60, THP-1, KG-1 and MV411 Concentration:Incubation Time:72 h Result:Inhibited cell growth with GI50s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively.RT-PCR Cell Line:THP-1 cells Concentration:72 h Incubation Time:0.1, 1 and 3 μM Result:Induced CDllb mRNA expression.
  • In Vivo
    Animal Model:MV411 mouse xenograft model Dosage:30 mg/kg Administration:Oral administration, twice daily for 21 days Result:Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    Dehydrogenase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1346705-53-0
  • Formula Weight
    441.88
  • Molecular Formula
    C24H21ClFNO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (282.88 mM; Ultrasonic )
  • SMILES
    ClC=1C=C(C=C(F)C1NC(=O)C2=C(C(O)=O)C=CC=C2)C3=CC(OCCCC)=CC=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Srikant Viswanadha, et al. Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia. Patent WO2021079273A1.
molnova catalog
related products
  • SW209049

    SW209049 is a stearoyl-CoA 9-desaturase inhibitor. SW209049 exhivits potent activity against H2122 cell with IC50 of 0.13uM.

  • (E/Z)-Ginkgolic acid...

    (E/Z)-Ginkgolic Acid C17:2 (Ginkgolic Acid C17:2) is a natural product extracted from Ginkgo biloba that targets human dihydroorotate dehydrogenase (DHODH).

  • MF-438

    MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1). In a mouse model, MF-438 shows an ED50 between 1 and 3 mg/kg.